Диссертация (1139681), страница 40
Текст из файла (страница 40)
Hypertension Primer: The Essentials of High Blood Pressure: Basic Science, Population Science, and Clinical Management. // Philadelphia, Pa: Lippincott Williams & Wilkins. -2003. -P. 382–384.166. Khafizianova R.Kh., Zimakov A.Y., Zimakova I.J., Karpov A.M. Antidepressant Therapj at the Dawn of the 3rd Millenium.
Castres-France. //-1997. -S. 19.167. Ko E., Sabanegh E. The role of over the counter supplements for thetreatment of male infertility – Fact or Fiction? // Journal of Andrology.-2011. Published Ahead of Print on May. –Vol. 324. -P. 678-721.168. Koster M. H., Musaph Р. Psyhosomatics in essential hypertension. //Karger, Basel. -1970. –Р. 234.169. Lahiri D.K., Nurnberger J. I. A rapid non-enzymatic method for thepreparation of HMW DNA from blood for RFLP studies.
// Nucleic AcidsRes. -1991. -Vol. 19. -S. 5444.170. Llorka P. Efficasy and safety of hydroxisyne in the treatment of generalized anxiety disorder: a 3–month double–blind study. // J. Clin.Psychiatry. -2002. -Vol. 63. -P. 1020–1027.171. Lloyd-Jones D.M., Evans J.C., Larson M.G. et al. Differential controlof systolic and diastolic blood pressure: factors associated with lack ofblood pressure control in the community. // Hypertension.
-2000. -Vol. 36.-n. 4. -P. 594–599.172. Maguire J.J., Kagan V., Ackrell A.C.B. Succinate-ubiquinone reductase linked recycling of alpha-tocopherol in reconstituted systems and mitochondria: requirement for reduced ubiquinone. // Arch. Biochem. Biophys.-1992. -Vol. 292. -P. 47–53.251173. Makinde T., Murphy R.F., Agrawal D.K. Immunomodulatory role ofvascular endothelial growth factor and angiopoietin-1 in airway remodeling.// Curr. Mol. Med.
-2007. –Vol. 6 . –n. 8. –P. 831–841.174. Massaglia G., Mantovani L.G., Sturkenboom M.C.J.M., Filippi A.,Patterns of persistence with antihypertensive medications in newly diagnosed hypertensive patients in Italy: a retrospective cohort study in primarycare. // J. Hypertens. -2005. -Vol. 23. -P. 2093-2100.175. Matsumoto T., Mugishima H. Signal transduction via vascular endothelial growth factor (VEGF) receptors and their roles in atherogenesis. //J. Atheroscler. Thromb. -2006. –Vol. 13. –n. 3. –P. 130–135.176.
Mejia A.D., Egan B.M., Schork N.J. Artefacts in measurement ofblood pressure and lack of target organ involvement in the assesment of patients with treatment-resistant hypertension. // Ann. Intern. Med. -1990.–Vol. 112. –C. 270-277.177. Mitrovic V., Patyna W., Huting R. Hemodynamic and neurohumoraleffects of moxonidine in patients with essential hypertension. // J. Cardiovasc. Drag.
Ther. -1991. -n. 5. –P. 967-972.178. Muxfeldt E.S., Bloch K.V., Nogueira AR et al. Twenty four hour ambulatory blood pressure monitoring pattern of resistant hypertension. //Blood Press Monit. -2003. –Vol. 8. – n. 5. -P. 181–185.179. Nahas R. Complementary and alternative medicine approaches toblood pressure reduction an evidence-based review. // Can Fam Physician.-2008. -54:1529–33.180. Neumann J., Ligtenberg G., Oey L.
Moxonidine normalizes sympathetic hyperactivit y in patients with eprosar tan-treated chronic renal failure.// J. Am. Soc. Nephrol. -2004. –Vol. 15. –P. 2902-2907.181. Nieto F.J., Young Т.В., Lind B.K. Association of sleep-disorderedbreathing, sleep apnea, and hypertension in a large community-based study.Sleep Heart Health Study. // JAMA. -2000. -Vol. 283.
-P. 1829-1836.182. Nishizaka M.K., Zaman M.A., Calhoun D.A. Efficacy of low-dose252spironolactone in subjects with resistant hypertension. // Am. J. Hypertens.-2003. -Vol. 16. -P. 925-930.183. Okonofua E.C., Simpson K.N., Jesri A. Therapeutic inertia is an impediment to achieving the healthy people 2010 blood pressure control goals.// Hypertension . -2006. -Vol. 47.
-P. 345-351.184. Ospina M.B., Bond K., Karkhaneh M. Meditation practices for health:state of the research. // Evid. Rep. Technol. Assess. -2007. -Vol. 155.–P. 1–263.185. Ouzan J., Perault C., Lincoff A.M., Carre E., Mertes M. The role ofspironolactone in the treatment of patients with refractory hypertension. //Am. J. Hypertension. -2002. -Vol. 15.
-P. 333-339.186. Padwal R.S., Hemmelgarn B.R., Khan N.A. The 2009 Canadian hypertension Education Program recommendations for the management of hypertension: Part 1 – blood pressure measurement, diagnosis and assessmentof risk. // Canadian Journal of Cardiology. -2009. -Vol. 25. –n. 5.–P. 279–286.187. Pall D., Katona E., Juhasz M. Prevention of target organ damage withmodern antihypertensive agents. // Orv. Hetil. -2006 -Vol. 147. –n. 32.-P.
1505–1511.188. Peppard P.E., Young T., Palta M., Dempsey J., Skatrud J. Longitudinal study of moderate weight change and sleep-disordered breathing. //JAMA. -2000. -Vol. 284. -P. 3015-3021.189. Pickering T.C., James G.D., Boddie C. et al. How common is whitecoat hy pertension? // JAMA. -1988.
–Vol. 259. -P. 225-228.190. Pimenta E., Gaddam K.K., Oparil S. Mechanisms and Treatment ofResistant Hypertension. // J. Clin. Hypertens. -2008. -Vol. 10. –n. 3.-P. 239-244.191. Pipinos I.I., Boska M.D. Pentoxifylline reverses oxidative mitochondrial defect in claudicating skeletal muscle. // J. Surg. Res. -2002.-Vol. 102. –n. 2. -P. 126–132.253192. Pisoni R., Ahmed M.I., Calhoun D.A. (2009) Characterization andtreatment of resistant hypertension. // Curr. Cardiol. Rep. -2009. -Vol.
11.–n. 6. -P. 407–413.193. Ram C.V. Management of refractory hypertension. //Am. J. Therapeutics. -2003. –n. 10. -P. 122-126.194. Rosenfeldt F.L., Haas S.J., Krum H., Hadj A., Ng K., Leong J-Y. et al.Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. // J. Hum. Hypertens. -2007.
-Vol. 21. –n. 4. -P. 297–306.195. Sadovsky Y. p300 regulates the synergy of SF-1 and Egr-1 in activating LHb gene. // J.Biol.Chem. -2004. -Vol. 279. –P. 7832-7839.196. Saha C., Eckert G.J., Ambrosius W.T., Chun T.Y., Wagner M.A. Improvement in blood pressure with inhibition of the epithelial sodium channelin blacks with hypertension. // Hypertension. -2005. -Vol. 46.
-P. 481-487.197. Samuelian J., Billardon M., Guillou N. Retentissmentsur les functionscognitives de deuxtraitmentsanxiolitiques chez des patients souffrantd’ anxietegeneralisee. // L’encephale. -1995. -Vol. 21. –P. 147.198. Schmaderer C., Eissler R., Seibel S., van Rooijen N. et al. Blood pressure control: a facelift for macrophages? // Hypertension. -2010. -Vol. 56.–P. 2-104.199. SchobersbergW., HoffmanG., Hobisch-Hagen P. Neopterin and 78dihydroneopterin induce apoptosis in the rat alveolar epithelial cell line. //FEBS Lett.
-1996. -Vol. 397. -P. 263-268.200. Sesso H.D., Buring J.E., Blake G.J. C-reactive protein and the risk ofdeveloping hypertension. // JAMA. -2003. -Vol. 290. –P. 2945–2951.201. Sever P.S., Messerli F.H. Hypertension management 2011: optimalcombination therapy. // Eur. Heart J. -2011. -Vol. 32. –n. 20. -P. 2499–2506.202. Sica D.A. Angiotensin receptor blockers: new considerations in theirmechanism of action. // J Clin Hypertens (Greenwich).
-2006. –Vol.8. –n. 5.–P. 381–385.254203. Singh R.B., Niaz M.A., Rastogi S.S., Shukla P.K., Thakur A.S. Effectof hydrosoluble coenzyme Q10 on blood pressures and insulin resistance inhypertensive patients with coronary artery disease. // J. Hum. Hypertens.-1999. -Vol. 13.
–n. 3. -P. 203–208.204. Sliwa K., Skudicky D., Candy G. Randomised investigation of effectsof pentoxifylline on left-ventricular performance in idiopathic cardiomyopathy. // Lancet. -1998. -Vol. 351. -P. 1091-1093.205. Sloand J.A., Balakrishnan S.L., Fong M.W., Bisognano J.D.
Evaluation and treatment of resistant hypertension. // Cardiology Journal. -2007.–Vol. 14. –n. 4. -P. 329–339.206. Sowers J.R., Whaley-Connell А., Epstein M. Narrative review: theemerging clinical implications of the role of aldosterone in the metabolicsyndrome and resistant hypertension. //Ann. Intern. Med. -2009. -Vol. 150.–n. 11. -P. 776–783.207. Staessen J.A., Fagard R., Thijs L. et al. For the Systolic Hypertensionin Europe (Syst-Eur). Trial Investigators.
Randomised double blind comparison of placebo and active treatment for older patients with isolated systolichypertension. // Lancet. -1999. –Vol. 350. –P. 57-64.208. Storkebaum E., Lambrechts D., Carmeliet P. VEGF: once regarded asa specific angiogenic factor, now implicated in neuroprotection. // Bio Essays. -2004. –Vol.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
